Stem Cell Research

Study Gains New Insight Into Stem Cell Regenerative Process And Organism Death

Stem Cell Regenerative Medicine is the controlled differentiation of stem cells into the functionally defined cells required to mend or replace sick or damaged tissue or organs.  Our bodies do this naturally, generating rather than regenerating a complete body from a single cell, growing and maintaining the body during our early years, maintaining it during adulthood, and then somehow allowing the process to deteriorate as the body ages and finally dies.

Shedding some new light on the process of aging and death, It turns out that the loss of two proteins,  the tumor-suppressor protein p53 and the DNA-maintenance protein ATR, results in tissues deteriorating rapidly generally resulting in death.

Essentially, argued senior author Eric Brown, PhD, Assistant Professor of Cancer Biology at the University of Pennsylvania School of Medicine, the findings highlight the fact that day-to-day maintenance required to keep proliferative tissues like skin and intestines functional is about more than just regeneration, the stem cell-based process that forms the basis of tissue renewal. It's also about housekeeping, the clearing away of damaged cells.

A Salute To Joanne Kurtzberg And The Duke University Division of Blood & Bone Marrow Stem Cell Transplantation

For the most part, stem cell research is still directed at finding basic understanding. Clinical trials continue to attempt to establish safety first and efficacy second. Meanwhile, Dr. Joanne Kurtzberg at Duke University is a standout medical scientist providing real solutions pioneered through the use of unrelated donor umbilical cord blood stem cells in patients who do not have a fully matched donor.  Her efforts and creativity have extended this life-saving therapy to many patients, most of them small children.

Under Kurtzberg's direction the program has performed over 1,400 autologous and allogeneic stem cell transplants in children with cancer or genetic diseases since 1990.

Hematopoietic stem cell transplant is provided as a treatment option for a variety of acquired and congenital disorders of children and young adults including hematopoietic malignancies and solid tumors including neuroblastoma and brain tumors, inherited immune deficiency syndromes, bone marrow failure syndromes, hemoglobinopathies, and inherited metabolic diseases.

Fate Therapeutics: A Further Look At Academic Stem Cell Researchers And The Private Sector That Will Market Their Results

Academic stem cell research pioneer entree into the world of markets and profit is always a trend worth watching. Today we're taking a quick look at Fate Therapeutics.

Among our Sector Companies, all of which are publicly traded, typically someone has suggested a possibility that business people see as a probability.  From there the emphasis is on obtaining approvals from public agencies, gaining market position, branding, and developing scalability, all toward the end of profitable sales. 

Examples range from companies that raise and spend public investor money primarily on research and development (such as Advanced Cell Technologies, Geron, Osiris and others) to those companies formed to market an already existing product or discovery (Neostem comes to mind here; the company has signed numerous partnership and license agreements, particularly in foreign markets, but has yet to spend money on research).

As research into regenerative medicine and stem cells progresses, capital will continue to seek knowledge, or vice versa, and new companies will enter the potential market place.  Academic researchers will be involved through actual participation in the formation and ongoing policy of the new entity or in an advisory capacity that most probably includes an ownership interest. 

Reflections On The Recently Reported Russian Nueral Stem Cell Tumor Case

In May 2001 at the age of 9 years, again in March 2002 and once more in July 2004 at the age of 12 years, a boy was taken by his parents to be treated in a Moscow hospital with a procedure involving a transplant of fetal stem cells into his brain. 

The boy suffers from a neurodegenerative hereditary disorder, ataxia telangiectasia (AT). AT is a childhood disease that causes degeneration of  those parts of the brain controlling muscle movements and speech. As a result of headaches an MRI was performed in an Israeli hospital in 2005 and a multifocal tumor was found in the boy's brain. Subsequent analysis proved the tumor could not have been generated by the boy's own cells and therefore had to originate with the transplanted stem cells. The following is from the story in TheScientist.com.

Cancer Stem Cells May Not Respond To Standard Cancer Treatments

All cancer cells were once thought to be equal, but recent research suggests otherwise. A growing body of evidence indicates that only certain cancer cells are capable of generating and maintaining a tumor. Dubbed cancer stem cells, they can divide indefinitely to perpetuate the cancer over time. They may also be the reason why some therapies fail to wipe out a cancer entirely: cancer stem cells seem to be particularly resistant to standard cancer treatments and can remain behind like the roots of a weed.

Time Of Day Influences Blood Stem Cell Collection Yield

When it comes to collecting human stem cells for clinical transplantation, picking the right time of day to harvest cells may result in a greater yield according to a new study.

An examination of healthy donors who were contributing HSCs for bone marrow transplantation at Mount Sinai Medical Center between the years of 2000 and 2006 revealed that the average yield was greater for those who underwent the procedure in the afternoon compared with those who were harvested in the morning.

Researchers at Mount Sinai School of Medicine were interested in examining whether circadian time continues to influence mobilization of hematopoietic stem cells (HSCs) when mice are treated with granulocyte-colony-stimulating factor (G-CSF), the most common stem cell mobilizer used in the clinic. The researchers found that after stimulation with G-CSF, synchronization of blood collection with the peak circadian time produced greater HSC recovery. Therefore, even when pharmacological manipulation is used to stimulate HSC mobilization, circadian clock genes continue to influence yield.

Adapted from the Mount Sinai School of Medicine announcement through EurekAlert.

A Cure For Cancer? The University of Oklahoma Thinks So

Apparently there is exists a particular protein that only appears in stem cells. Until now, researchers knew of proteins that appeared in both regular cancer cells and stem cells, but none that was unique to stem cells. Finding one that that is could provide a cure for cancer.

Focusing on adult cancer stem cells (adult stem cells work as essential building blocks in organs by replenishing dying cells and regenerating damaged tissues) because of the major role they play in the start, growth, spread and return of cancer, the University of Oklahoma team, led by by Courtney Houchen, M.D., and Shrikant Anant, Ph.D., has already begun work to target the protein with a new compound that, once developed, would kill the stem cells and kill the cancer. By targeting the stem cells, scientists and physicians also would be able to stop the cancer from returning.

Overcoming Obstacles In Cord Blood Stem Cell Transplants

Bone marrow stem cell transplants represent the broadest and longest used form of stem cell regenerative therapy.  Various blood cancers (including myeloma, lymphoma and leukemia) have been treated since the seventies by destroying a patient's immune system with radiation and chemotherapy and then replacing it with a regenerated immune system initiated through the transplanting of bone marrow stem cells.

Bone marrow stem cells are available in cord blood (collected from the umbilical cord after the baby is delivered and separated from the cord). One of the fastest growing segments of industry generated by stem cell research is in companies that collect and cryogenically preserve cord blood and those that produce the equipment used to do it.

Cord blood is increasingly being used by transplant centers as an alternative source of stem cells for the treatment of blood cancers. Cord blood stem cells have a greater proliferative capacity than adult bone marrow stem cells and a greater number of stem cells are found in cord blood than in adult bone marrow or peripheral blood. Promising uses of cord blood stem cells outside the cancer arena are currently being researched. But right now these stem cells are most commonly used for bone marrow transplantation when a donor from a patient’s family or an unrelated donor does not produce an appropriate bone marrow match.

Cancer: Research Closes Bad But Well Traveled Road

    A lot of research and more than a few researchers have assumed that tumor angiogenesis (angiogenesis is a big word for the physiological process of growing new blood vessels from pre-existing ones) and cancer growth depend on circulating endothelial precursor cells (endothelial cells are the cells that make up the lining of blood vessels.  Endothelial precursor suggests a stem cell that has 'decided' to become a cell that makes up the lining of blood vessels). And apparently their assumptions have been wrong.

Cancer: Cell to Cell Communication, Answer To Stopping Tumor Growth?

  This recent finding suggests that there is a difference between normal stem cells and cancer stem cells that can be exploited and that Notch inhibition might be successfully used to target tumor stem cells in humans.

   In a new 30 patient, metastatic breast-cancer trial getting under way at University of Michigan and two other locations, so-called Notch inhibitors will be used to attack the small percentage of tumor cells that are stem cells.  Notch signaling pathways send signals from a cell's surface membrane into its nucleus.  Such communication activates genes that instruct the cell to make proteins that perform various tasks.  The idea of inhibiting notch communications to stop the stem cells from expanding a tumor raised a concern that normal blood-forming stem cells would be inhibited as well.  Reproduction of various blood stem cells is responsible for the recreation of literally billions of new, very necessary cells in each of us every day.